DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.

Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:

  • Royalty-free to ensure the lowest possible price
  • Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
  • Worldwide coverage both for R&D and for manufacture
  • Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)

An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.

 

Pharmaceuticals

AbbVie (USA) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L  / Chagas C205 Series / Flubendazole Macrofilaricide / AbbV4083 / ‘4-in-1’ LPV/r/ABC/3TC

Astellas Pharma (Japan) – Projects: Screening

AstraZeneca (UK) – Projects: ScreeningLead optimization/ Leish H2L / Chagas H2L

Avista Pharma (formerly SCYNEXIS) (USA) – Projects: Acoziborole / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi 5610

Bayer Healthcare (Germany) – Projects: ScreeningEmodepside

Bristol-Myers Squibb (USA) – Projects: Screening

Cipla Inc. (India) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI / ASMQ

Daiichi Sankyo (Japan) – Projects: Screening / Daiichi Sankyo LH2L / Daiichi Sankyo CH2L

Debiopharm (Switzerland) – Projects: Discovery

Eisai Co., Ltd. (Japan) – Projects: Screening  /  Leish H2L / Chagas H2L / Azoles E1224New benz regimens +/- fosravuconazole / Fosravuconazole

E.I du Pont Nemours (USA) – Projects: Screening

Farmanguinhos (Fiocruz) (Brazil) – Projects: ASMQ

GeneDesign Inc. (Japan) – Projects: CpG-D35

Gilead Sciences (USA) – Projects: Fexinidazole (HAT) 

GlaxoSmithKline (Spain) – Projects: Screening / Lead optimization / Leish H2L / New treatments for HIV/VL / Chagas C205 series / Chagas H2L 

GNF Novartis, Genomics Institute of the Novartis Research Foundation (USA) – Projects: Screening

Humax Pharmaceutical (Colombia) – Projects: Anfoleish

Johnson & Johnson (USA) – Projects: ScreeningFlubendazole Macrofilaricide

Janssen (Belgium) – Projects: Screening

Janssen Research & Development (USA) – Projects: Flubendazole Macrofilaricide

LAFEPE (Brazil) – Projects: Paediatric dosage form of benznidazole

Mercachem (The Netherlands) – Projects: Screening

Merck (USA) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L

Merck Serono (Germany) – Projects: Screening

Optimed (France) – Projects: Fexinidazole-Miltefosine combination

Paladin Labs (Canada) – Projects: VL-0208

Pharco Pharmaceuticals Inc. (Egypt) – Projects: Ravidasvir/ Sofosbuvir

Pfizer Ltd. (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles

Sanofi (France) – Projects: Screening / Lead optimization/ Leish H2L / Chagas H2L / Chagas C205 series / ASAQ / Fexinidazole (HAT) 

Sanofi-Chinoin (Hungary) – Projects: Fexinidazole-Miltefosine combination

Sara Pharm (Romania) – Projects: DNDi-6148

Shionogi & Co. Ldt (Japan) – Projects: Screening / Leish H2L / Chagas H2L

Syngene (India) – Projects: DNDi-6148 / DNDi-0690

Takeda Pharmaceutical Company Ltd. (Japan) – Projects: Screening / Aminopyrazoles /  Leish H2L / Chagas H2L / DNDi-5561

Zenufa Laboratories Ltd (Tanzania) – Projects: ASAQ

top of the page

 

Biotechs

Anacor Pharmaceuticals (USA) – Projects: Screening / Lead optimization / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / Acoziborole / DNDi-6148 / Oxachagas / Chagas C205 series

Celgene Global Health (USA) – Projects: Screening / Lead optimization / CGH VL series 1 / Chagas C205 series

Evolva (Switzerland) – Projects: Discovery

Genzyme (USA) – Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.

  iThemba Labs (South Africa) – Projects: Lead optimization

Polytherics (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.

SCYNEXIS Inc. (USA) – Projects:  Lead optimization /  SCYX-2035811 / SCYX-1330682 SCYX-1608210 / Acoziborole / DNDi-5421 DNDi-5610 / DNDi-6148

Sequella, Inc. (USA) – Projects: Screening

Vertex (USA) – Projects: Screening

top of the page

 

Universities

Addis Ababa University (Ethiopia) – Projects: VL-0208New treatments for HIV/VL / SSG&PM

Banaras Hindu University, Institute of Medical Sciences (India) – Projects: New treatments for PKDL

Baylor College of Medicine Children’s Foundation (Uganda) – Projects: LPV/r pellets with dual NRTI

Brasilia University (Brazil) – Projects: New VL treatments Latin America

Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) – Projects: Fexinidazole-Miltefosine combination

Federal University of Sergpipe (Brazil) – Projects: New VL treatments Latin America

Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) – Projects: Lead optimization / Leish H2L / Chagas H2L / Chagas C205 series

Gondar University Hospital (Ethiopia) – Projects: VL-0208 / Miltefosine-Paromomycin combination for AfricaNew treatments for HIV/VL / SSG&PM 

Imperial College (UK) – Projects: Formulation of amphotericin B with Polytherics.

London School of Hygiene and Tropical Medicine (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles / VL-0208 / VL-2098DNDi-5421 DNDi-5610 / CGH VL series 1Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / SSG&PM / New VL treatments Asia / Nitroimidazole / OxachagasChagas H2L / Biomarkers /  Chagas C205 series

London School of Pharmacy (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.

Makarere University (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

McGill University (Canada) – Projects: Biomarkers / Flubendazole Macrofilaricide

Michigan State University (USA) – Projects: Flubendazole Macrofilaricide

Monash University, Centre for Drug Candidate Optimization (Australia) – Projects: Lead optimization / Fenarimol / Chagas H2L / Leish H2L / Chagas C205 series

Murdoch University, School of Veterinary and Biomedical Science (Australia) – Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization / Chagas C205 series

Montes Claros State University (Brazil) – Projects: New VL treatments Latin America

Nagasaki University (Japan) – Projects: CpG-D35

Ohio State University (USA) – Projects: CpG-D35

Pace University (USA) – Projects: SCYX-2035811 / SCYX-1330682 SCYX-1608210

Piaui Federal University (Brazil) – Projects: New VL treatments Latin America

Radboud University Medical Center (The Netherlands) – Projects: Fosravuconazole

Stellenbosch University (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Universidad Autónoma Juan Misael Saracho (Bolivia) – Projects: Biomarkers / Azoles E1224New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)

Universidade Estadual de Campinas UNICAMP (Brazil) – Project: Lead Optimization / Leish H2L / Chagas H2L / Chagas C205 series

 University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology (Germany) – Projects: Screening / Macro Filaricide 3 

Universidad Mayor de San Simon (Bolivia) – Projects: Biomarkers / Azoles E1224New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)

Universidad Peruana Cayetano Heredia (Peru) – Projects: New CL combination therapies

Universidad San Martin (Argentina) – Projects: Biomarkers 

Universidade Estadual do Rio de Janeiro (Brazil) – Projects: New VL treatments Latin America

University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (Colombia) – Projects: Anfoleish / New CL combination therapies

University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) – Projects: Screening / Lead optimization  / Leish H2L / Chagas H2L / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi-5610 / Aminopyrazoles / DNDi-6148 / DNDi-0690VL-0208 / CGH VL series 1  / Nitroimidazole / OxachagasChagas C205 series

 University of Auckland (New Zealand) – Projects: Lead optimization / SCYX-2035811 / Nitroimidazole / DNDi-0690

 University of Buea (Cameroon) – Projects: Flubendazole Macrofilaricide

University of Cape Town, Division of Clinical Pharmacology Department of Medicine (South Africa) – Projects: ScreeningSuperbooster therapy paediatric HIV/TB

University of Dundee, Drug Discovery Unit (UK) – Projects: Screening / Leish H2L / Chagas H2L / Chagas C205 series

University of Nairobi (Kenya) – Projects: LPV/r pellets with dual NRTI

University of Osaka (Japan) – Projects: CpG-D35

 University of Witswatersrand, Perinatal HIV Research Unit (South Africa) – Projects: Superbooster therapy Paediatric HIV/TB

University of Texas at El Paso (USA) – Project: Biomarkers

Uppsala University (Sweden) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa

Utrecht University (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infectionMiltefosine-Paromomycin combination for Africa

Various academic partners (South Africa and Kenya) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

 University of California (UCSF), San Francisco (USA) – Projects: K777Superbooster therapy Paediatric HIV/TB

University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.

Universidade Ouro Preto (Brazil) – Projects: Fenarimol / Nitroimidazole / Lead Optimization

University of Oxford, Worldwide Antimalarial Drug Resistance Network (UK) – Projects: ASAQ (Malaria) / ASMQ (Malaria)

University Sains (Malaysia) – Projects: ASAQ (Malaria) / ASMQ (Malaria)

top of the page

 

University “Spin-off”

Epichem (Australia) – Projects: Screening / Leish H2LChagas H2L / Lead optimization / Fenarimol / Chagas C205 series

Eskitis Institute for Cell and Molecular Therapies, Griffith University (Australia) – Projects: ScreeningLead optimization/ Chagas H2L / Leish H2L / Chagas C205 series

top of the page

 

Research Institutes

Broad Institute, MIT and Harvard (USA) – Projects: Discovery activity for Chagas disease

Dr Mario Fatala Chaben National Institute of Parasitology (Argentina) – Projects: Biomarkers

 Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (FIPEC) (Argentina) Projects: Clinical studies for Chagas disease.

Georges Institute for International Health (Australia) – Projects: ASAQ

Ifakara Health Institute (Tanzania) – Projects: ASMQ

IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) – Projects: ASAQ

Institut de Recherche pour le Développement (IRD) (France) – Projects: Acoziborole / Fexinidazole (HAT) 

 Institut de Recherche pour le Développement (IRD) (Sénégal) – Projects: ASAQ

Institut National de Recherche Biomédicale (DRC) – Projects: Acoziborole / Fexinidazole (HAT) 

Institute of Tropical Medicine Antwerp (Belgium) – Projects: Acoziborole/ Fexinidazole (HAT) / New treatments for HIV/VL  / VL-0208 / New VL treatments Asia

Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) – Projects: New benz regimens +/- fosravuconazole  / Paediatric dosage form of benznidazole

 Institute of Endemic Disease (IEND), Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) – Projects: VL-0208 / SSG&PM / Fexinidazole-Miltefosine combination / New treatments for PKDL / Fosravuconazole / Miltefosine-Paromomycin combination for Africa 

Institut Pasteur (France) – Projects: Screening

 Institut Pasteur Korea (South Korea) – Projects: Screening / Leish H2LChagas H2L / Fenarimol / Chagas C205 series

Kenya Medical Research Institute (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa / LPV/r pellets with dual NRTI / SSG&PM / ASAQ / ASMQ

Kononklijk Instituut voor de Tropen (The Netherlands) – Projects: Fexinidazole-Miltefosine combination

Medical Research Council (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

National Institutes of Health (USA) – Projects: Screening / CpG-D35

Necker Institute (France) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

Northwick Park Institute for Medical Research (UK) – Projects: Screening / Macro Filaricide 3

Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) – Projects: New treatments for PKDL / New VL treatments Asia

Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

The Netherlands Cancer Institute (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa

The Swiss Tropical and Public Health Institute (Switzerland) – Projects: Screening / Leish H2LChagas H2L / Acoziborole / Fexinidazole (HAT) / NECT / SSG&PM / LPV/r pellets with dual NRTI

University of Georgia Research Foundation (USA) – Projects: Biomarkers

University of Georgia, The Center for Tropical and Emerging Global Diseases (CTEGD) (USA) – Projects: Azoles E1224

Walter Reed Army Institute (USA) – Projects: Screening

top of the page

 

National Research Centres

Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) (Argentina) – Projects: Paediatric dosage form of benznidazole 

B.P Koirala Institute of Health Sciences (Nepal) – Projects: Clinical trials for visceral leishmaniasis.

 Brazilian Biosciences National Laboratory (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) (Brazil) – Projects: Screening / Lead optimization / Chagas H2L / Chagas C205 series

 Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso) – Projects: ASMQ

 Central Drug Research Institute (CDRI) (India) – Projects: VL-2098 / DNDi-0690

 Council of Scientific and Industrial Research (CSIR) (India) – Projects: Various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.

Erasmus Medical Centre (The Netherlands) – Projects: Fosravuconazole

Fiocruz, Fundaçao Oswaldo Cruz (Brazil) – Projects: Azoles E1224

Indian Council of Medical Research (ICMR) (India) – Projects: New VL treatments Asia / ASAQ / ASMQ

International Centre for Diarrhoeal Disease Research (Bangladesh) – Projects: New treatments for PKDL / New VL treatments Asia

IS Global, Centre de Recerca en Salut Internacional de Barcelona (CRESIB) (Spain) – Projects: Screening /  Biomarkers / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)Azoles E1224

Joint Clinical Research Centre (Uganda) – Projects: LPV/r pellets with dual NRTI

Kala Azar Medical Research Centre (India) – Projects: New treatments for PKDL / New VL treatments Asia

Medical Research Council (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

Mycetoma Research Centre, Soba University Hospital (Sudan) – Projects: Fosravuconazole

National Institute for Medical Research (NIMR) (Tanzania) – Projects: ASMQ

National Vector Borne Disease Control Programme (India) – Projects: New VL treatments Asia

Northwick Park Institute for Medical Research (UK) – Projects: Screening

Novartis Centre de la Recherche Santé Animale (Switzerland) – Projects: Screening

Rene Rachou Research Center, Fiocruz MG (Brazil) – Projects: New VL treatments Asia / New VL treatments Latin America

Seattle Biomedical Research Institute (USA) – Projects: Discovery for NTDs.

Texas Biomedical Research (USA) – Projects: Biomarkers

top of the page

 

NGOs/IOs

AEDES, consulting firm for Social and Public health sector (Belgium) – Projects: ASAQ

Clinton Access Health Initiative (USA) – Projects: LPV/r pellets with dual NRTI

Collective of Applied Studies and Social Development (CEADES) (Bolivia) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)

Communauté Baptiste du Congo (CBCO) (Democratic Republic of Congo) – Projects: Fexinidazole (HAT)

Epicentre (France) – Projects: NECT / ASAQ / ASMQ

Epicentre Research Center (Uganda) – Projects: LPV/r pellets with dual NRTI

Fundación Mundo Sano and ELEA (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole

IDA Foundation (The Netherlands) – Projects: VL-0208 / SSG&PM

i+solutions (The Netherlands) – Projects: VL-0208 / SSG&PM / New treatments for PKDL

Médecins Sans Frontières – Projects: ASAQ  / NECT / Fexinidazole (HAT) / Fexinidazole-Miltefosine combination  / New treatments for HIV/VL  / VL-0208 / New VL treatments Asia / SSG&PM  / Generic Ambisome /  Biomarkers / Azoles E1224 / Fexinidazole (Chagas) / ‘4-in-1’ LPV/r/ABC/3TC 

Microbial Chemistry Research Foundation (Japan) – Projects: Screening

 Offre Technique d’Etude et de Coopération Internationale (OTECI) (France) – Projects: ASMQ

Royal Society of Chemistry (UK): MoU to promote open source discovery.

UNITAID (Switzerland) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI

WHO-TDR: (Switzerland) – Projects: ASAQ / ASMQ / Screening / New VL treatments Asia

top of the page

 

PDPs/PPPs

FIND, Foundation for Innovative New Diagnostics (Switzerland) – Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.

Medicines for Malaria Venture (MMV) (Switzerland) – Projects: Screening / ASAQ / ASMQ

Novartis Institute for Tropical Diseases (Singapore) – Projects: Lead optimization

 Institute for One World Health (OWH) (USA) – Projects: VL-0208 / New VL treatments Asia / SSG&PM

TB Alliance (USA) – Projects: NitroimidazoleSCYX-2035811 / VL-2098 / Screening / Lead optimization/ DNDi-0690

TI Pharma (The Netherlands) – Projects: DNDi partner for discovery activities.

top of the page

 

Hospitals

Amudat General Hospital (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / Miltefosine-Paromomycin combination for Africa

Arba Minch Hospital (Ethiopia) – Projects: SSG&PM

CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland) – Projects: ASMQ

Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Gertrude’s Children’s Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

Hospital de Niños de Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole 

Hospital de Niños Dr. Ricardo Gutiérrez (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole

Hospital General Universitari de Valencia (Spain) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)

Hospital Independencia, Centro de Chagas y Patologia Regional (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole

Hospital Público Materno Infantil (Argentina) – Projects: Paediatric dosage form of benznidazole

Hospital Sao José de Doencas Infecciosas (Brazil) – Projects: New VL treatments Latin America

 Kacheliba District Hospital (Kenya) – Projects: Fexinidazole-Miltefosine combination

 KATH, Komfo Anokye Teaching Hospital (Ghana) – Projects: ASAQ

Mbagathi District Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

Moi Teaching and Referral Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

 National Museum of Natural History Paris (MNHN) (France) – Projects: Screening

Paediatric Hospital Joao Paulo II – FHEMIG (Brazil) – Projects: New VL treatments Latin America

Shaheed Suhrawardy Medical College and Hospital (Bangladesh) – Projects: New VL treatments Asia

St. Lumumba Health Centre (Kenya) – Projects: LPV/r pellets with dual NRTI

Tygerberg Children’s Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

University Hospitals of Geneva (Switzerland) – Projects: Biomarkers / Macro Filaricide 3

top of the page

 

Ministries of Health/Governmental Organizations

Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP) Projects: Various partnerships for clinical trials in the field of leishmaniasis / VL-0208 / SSG&PM

Bihar State Health Society (India) Projects: New VL treatments Asia

Centre for Disease Control and Prevention CDC/President’s Emergency Plan for AIDS Relief (USA) Projects: ‘4-in-1’ LPV/r/ABC/3TC

 Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias (CeNDIE), Ministry of Health, (Argentina) Projects: Paediatric dosage form of benznidazole

Clinical Research Malaysia, Ministry of Health (Malaysia) Projects: Ravidasvir/Sofosbuvir

Department of Health and Department of Science and Technology (South Africa) Projects: Superbooster therapy paediatric HIV/TB

Department of Health South Africa (South Africa) Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI

 Food & Drug Administration (FDA) (US) Projects: CpG-D35

Ministry of Health, Leishmaniasis Control Programme (Brazil) Projects: New VL treatments (Latin America)

 Ministry of Health, National Malaria Control Programme (Burundi) Projects:  ASAQ

Ministry of Health (Cambodia) Projects: ASMQ

Ministry of Health (DRC) Projects: Various partnerships (financial and clinical trial agreement) in the field of HAT / NECT

Ministry of Health (Ethiopia) Projects: SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Ghana) Projects: ASAQ

Ministry of Health (Kenya) Projects: LPV/r pellets with dual NRTI / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Sierra Leone) Projects: ASAQ

Ministry of Health (Sudan) Projects: New treatments for PKDL / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Uganda) Projects: SSG&PM / VL-0208

Ministry of Health and Family Welfare (Bangladesh) Projects: New VL treatments Asia

Ministry of Health, Province of Jujuy (Argentina) Projects: Paediatric dosage form of benznidazole

National Trypanosomiasis Control Programme (DRC) Projects: NECT / Acoziborole 

top of the page

 

Contract Research Organizations (CROs)

Accelera (Italy) – Projects: VL-2098 / DNDi-0690 / DNDi-6148

Advinus Therapeutics Ltd. (India) – Projects:  Acoziborole / VL-2098 / DNDi-0690 

Aptuit (Italy) –  Projects: DNDi-0690 / Fexinidazole-Miltefosine combination / VL-2098 / Fexinidazole (HAT)

BaseCon (Denmark) Projects: Fexinidazole-Miltefosine combination  / New treatments for HIV/VL

Bertin Pharma (France) Projects: ASAQ (Malaria) / VL-2098 / Acoziborole / Fexinidazole (HAT)

Cardiabase (France) Projects: Fexinidazole-Miltefosine combination / Acoziborole / Fexinidazole (HAT)

Calvert Labs (USA) Projects: Pre-clinical phase for topical formulation against cutaneous leishmaniasis.

Cardinal System (France) Projects: Azoles E1224

Catalent (USA) Projects: Screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.

Centipharm (France) Projects: CMC/manufacture of fexinidazole for HAT.

Central Diagnostics (India) Projects: Partner in the field of visceral leishmaniasis.

Clinwin Research Services (Kenya) Projects: ASMQ (Malaria)

CoreLab Partners (USA) Projects: Clinical activity for Chagas disease.

Covance (UK) Projects: VL-2098

Creapharm (France) Projects: Fexinidazole (Chagas)

Drugabilis (France) Projects: Screening & Lead Optimization / Fexinidazole (HAT) / Oxaborole SCYX-7158 (HAT) / Flubendazole (Filarial diseases) / VL-2098

Endolytics (USA) Projects: VL-2098

Eurofins Optimed (France) Projects: Oxaborole SCYX-7158 (HAT) / Two “4-in-1” LPV/r based FDC granules (Paediatric HIV)

Frontage (USA) Projects: Azoles E1224 & Biomarker (Chagas)

GVK Biosciences (India) Projects: Clinical phase for malaria and VL.

Harlan Laboratories (Switzerland) Projects: Pre-clinical research agreement for Chagas disease.

Huntingdon Life Sciences Limited (UK) Projects: VL-2098

Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres”, National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) Projects: New benz regimens +/- fosravuconazole  / Fexinidazole (Chagas) / Biomarkers /  Azoles E1224 / Paediatric dosage form of benznidazole

JSS Medical Research (Canada) Projects: Anfoleish (CL) / Fexinidazole (Chagas)

LAT Research (Argentina) Projects: Azoles E1224 & Biomarker (Chagas)

Nucleo de desenvolvimento farmacêutico e cosméticos  (NUDFAC) (Brazil) Projects: Azoles E1224 & Biomarker (Chagas) / Paediatric Benznidazole (Chagas)

Patheon (UK) Projects: Formulation development and manufacturing for HAT.

Penn Pharmaceuticals Services (UK) Projects: Oxaborole SCYX-7158 (HAT)

PhinC (France) – Projects: Fexinidazole-Miltefosine combination

RCTs (France) Projects: NECT (HAT) / Fexinidazole (HAT)

Roowin (France) Projects: CMC activities for HAT.

Sandexis (UK) Projects: Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148

Selcia (UK) Projects: VL-2098

Sigma-Aldrich (UK) Projects: VL-2098

SGS (France). Projects: Clinical study of fexinidazole for HAT, subsequently performing bioanalyses.

SGS (Belgium) Projects: Fexinidazole-Miltefosine combination

Theradis Pharma (France) Projects: Fexinidazole (HAT)

WuXi AppTech (China) Projects: Screening/ Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148 / DNDi-0690 / Two ‘4-in-1’ LPV/r based FDC granules

top of the page

 

Platforms and Networks

HAT Platform Projects: NECT

Leishmaniasis East Africa Platform Projects: Fexinidazole-Miltefosine combination / New treatments for PKDL / New treatments for HIV/VL coinfection / SSG&PM

National Control Programmes of the DRC and CAR Projects: Fexinidazole

NHEPACHA Network Projects: Biomarkers

Platform of Integral Care for Patients with Chagas Disease (Bolivia) Projects: New benznidazole regimens/ Fexinidazole

top of the page

 

 

Please contact us at partnership@dndi.org to propose collaborative projects.

top of the page